Pediatric Thymoma Treatment & Management

  • Author: Cecilia P Mikita, MD, MPH; Chief Editor: Harumi Jyonouchi, MD   more...
 
Updated: Aug 12, 2010
 

Medical Care

  • Postoperative radiotherapy has been used for invasive thymoma and incompletely resected thymoma.
    • Commonly, radiotherapy has treated T tumors demonstrated to be unresectable on CT scan or with supraclavicular extension.
    • Primary radiotherapy in unresectable stage III or stage IVa disease has controlled local disease with a 5-year survival rate of 45-50%.[2]
    • Combination chemotherapy using cisplatin has been reported to have a response rating of 70-80%. Doxorubicin, vincristine, and cyclophosphamide have been used in combination chemotherapy.
  • The acquired immunodeficiency associated with thymoma should be treated with monthly replacement immunoglobulin (Ig) therapy. Replacement Igs may be intravenously or subcutaneously administered. Doses of intravenous Igs should be 300-400 mg/kg every 3 weeks or 400-500 mg/kg every 4 weeks with dose adjustment to maintain trough IgG levels above 500-600 mg/dL. In addition, prophylactic antibiotics may be required in addition to Ig replacement therapy to prevent bacterial infections in immunodeficient patients. Aggressive and long-term antibiosis is often required to treat bacterial infections in these patients.[21]
Next

Surgical Care

  • Because thymoma is usually well encapsulated and characterized by local spread, thymectomy can be curative in the early stages.
    • Encapsulated (stage I) tumors can usually be completely excised, and the local relapse rate is less than 5%. The relapse rate increases in more invasive stages.
    • Surgery can be challenging because of the tendency of the tumor to surround blood vessels, bronchi, and other mediastinal structures. Excessive bleeding can complicate thymectomy of large tumors that have become vascular or lacunar.
    • Tumor recurrence can occur even after complete resection.[29]
  • Eighty-five percent of patients with myasthenia gravis (MG) have some histologic abnormality of the thymus.
    • Thymectomy is considered a routine treatment for MG. Reportedly, resection of the thymoma is associated with improvement in weakness in 25% of patients, and almost one half of patients without thymoma improve after thymectomy.[13]
    • A recent study of 153 patients by Werneck et al compared thymectomy with conservative treatment groups in paired patients at similar stages and found no statistical difference between the conservative treatment and thymectomy groups.[30]
    • Thymectomy is believed to improve muscle weakness in 25% of individuals with MG and thymoma and in 50% of patients with MG without thymoma.
  • Thymectomy results in resolution of red cell aplasia in 30% of persons with this disorder.
  • The acquired immunodeficiency phenotype does not improve after thymectomy, and, in some persons, immunodeficiency has occurred years after resection of a thymoma.[31]
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Cecilia P Mikita, MD, MPH  Associate Program Director, Allergy-Immunology Fellowship, Associate Professor of Pediatrics and Medicine, Uniformed Services University of the Health Sciences; Hospital Intern Director, Staff Allergist/Immunologist, Walter Reed Army Medical Center

Cecilia P Mikita, MD, MPH is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, and Clinical Immunology Society

Disclosure: Nothing to disclose.

Coauthor(s)

Richard A Bickel, MD  Fellow in Allergy/Immunology, Walter Reed Army Medical Center

Richard A Bickel, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Terry W Chin, MD, PhD  Associate Director, Pediatric Allergy/Immunology/Pulmonology, Miller Children's Hospital, Long Beach Memorial Medical Center; Associate Professor, Department of Pediatrics, University of California, Irvine, School of Medicine

Terry W Chin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American College of Chest Physicians, American Thoracic Society, California Thoracic Society, Clinical Immunology Society, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David J Valacer, MD  Consulting Staff, Hoffman La Roche Pharmaceuticals

David J Valacer, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American Thoracic Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

David Pallares, MD  Clinical Assistant Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Louisville School of Medicine

David Pallares, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD  Associate Professor, Division of Pulmonary, Allergy/Immunology, and Infectious Diseases, Department of Pediatrics, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Mucosal Immunology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Marion Johnson, MD, to the development and writing of this article.

References
  1. Stites DP. Diseases of the thymus. In: Wyngaarden J, Smith LH, eds. Cecil Textbook of Medicine. WB Saunders Co; 1988.

  2. Rich RR. Clinical Immunology, Principles and Practice. 2nd ed. Mosby; 1996.

  3. Roitt IM, Brostoff J, Male DK. Immunology. 5th ed. Mosby; 1998.

  4. Temes R, Chavez T, Mapel D, et al. Primary mediastinal malignancies: findings in 219 patients. West J Med. Mar 1999;170(3):161-6. [Medline].

  5. Agarwala SS. Paraneoplastic syndromes. Med Clin North Am. Jan 1996;80(1):173-84. [Medline].

  6. Mygland A, Vincent A, Newsom-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. Apr 2000;57(4):527-31. [Medline].

  7. Fauci AS, Braunwald E, Isselbacher KJ. Harrison's Principles of Internal Medicine. 14th ed. McGraw-Hill; 1998.

  8. Hart IK. Acquired neuromyotonia: a new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci. Apr 2000;319(4):209-16. [Medline].

  9. Evoli A, Minicuci GM, Vitaliani R, et al. Paraneoplastic diseases associated with thymoma. J Neurol. Jun 2007;254(6):756-62. [Medline].

  10. Takamori M, Komai K, Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am J Med Sci. Apr 2000;319(4):204-8. [Medline].

  11. Ammann AJ, Stiehm ER, Roberts RL. Antibody (B-cell) immunodeficiency disorders. In: Stites DP, Terr A, eds. Medical Immunology. Appleton & Lange; 1997.

  12. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. Mar 7 1996;334(10):630-3. [Medline].

  13. Frank K, Austin M. Samter's Immunologic Diseases. Little Brown & Co; 1995.

  14. Strollo DC, Rosado de Christenson ML, Jett JR. Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. Chest. Aug 1997;112(2):511-22. [Medline].

  15. Stiehm ER. Immunologic disorders in infants and children. In: Ochs HD, Winkelstein J, eds. Disorders of the B-Cell System. 4th ed. 1996:320.

  16. Watts RG, Kelly DR. Fatal varicella infection in a child associated with thymoma and immunodeficiency (Good's syndrome). Med Pediatr Oncol. 1990;18(3):246-51. [Medline].

  17. Middleton E, Reed CE, Ellis EF, et al, eds. Allergy: Principles and Practice. 5th ed. Mosby; 1998.

  18. Loehrer PJ Sr. Current approaches to the treatment of thymoma. Ann Med. Oct 1999;31 Suppl 2:73-9. [Medline].

  19. Takeda S, Miyoshi S, Akashi A. Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution. J Surg Oncol. May 2003;83(1):24-30. [Medline].

  20. Takanami I, Takeuchi K, Naruke M. Noninvasive large thymoma with a natural history of twenty-one years. J Thorac Cardiovasc Surg. Dec 1999;118(6):1134-5. [Medline].

  21. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. May 2005;94(5 Suppl 1):S1-63. [Medline].

  22. Kelleher P, Misbah SA. What is Good's syndrome? Immunological abnormalities in patients with thymoma. J Clin Pathol. Jan 2003;56(1):12-6. [Medline].

  23. Camera L, Brunetti A, Romano M, et al. Morphological imaging of thymic disorders. Ann Med. Oct 1999;31 Suppl 2:57-62. [Medline].

  24. Lastoria S, Palmieri G, Muto P, Lombardi G. Functional imaging of thymic disorders. Ann Med. Oct 1999;31 Suppl 2:63-9. [Medline].

  25. Panitch HS. Neurologic diseases. In: Stites DP, Terr AI, Parslow TG, eds. Medical Immunology. Appleton & Lange; 1997.

  26. Muller-Hermelink HK, Marx A. Pathological aspects of malignant and benign thymic disorders. Ann Med. Oct 1999;31 Suppl 2:5-14. [Medline].

  27. Bott-Kothari T, Aron BS, Bejarano P. Malignant thymoma with metastases to the gastrointestinal tract and ovary: a case report and literature review. Am J Clin Oncol. Apr 2000;23(2):140-2. [Medline].

  28. Kim DJ, Yang WI, Choi SS. Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest. Mar 2005;127(3):755-61. [Medline].

  29. Okumura M, Shiono H, Inoue M, et al. Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system. J Surg Oncol. Jan 1 2007;95(1):40-4. [Medline].

  30. Werneck LC, Cunha FM, Scola RH. Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment. Acta Neurol Scand. Jan 2000;101(1):41-6. [Medline].

  31. Raschal S, Siegel JN, Huml J, Richmond GW. Hypogammaglobulinemia and anemia 18 years after thymoma resection. J Allergy Clin Immunol. Dec 1997;100(6 Pt 1):846-8. [Medline].

  32. Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg. Aug 2008;86(2):673-84. [Medline].

  33. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol. Aug 1990;8(8):1419-23. [Medline].

  34. Macchiarini P, Chella A, Ducci F, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer. Aug 15 1991;68(4):706-13. [Medline].

  35. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. Sep 1997;15(9):3093-9. [Medline].

  36. Venuta F, Rendina EA, Pescarmona EO, et al. Multimodality treatment of thymoma: a prospective study. Ann Thorac Surg. Dec 1997;64(6):1585-91; discussion 1591-2. [Medline].

  37. Palmieri G, Lastoria S, Montella L, et al. Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. Ann Med. Oct 1999;31 Suppl 2:80-5. [Medline].

  38. Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. Mar 1 1985;55(5):1074-86. [Medline].

  39. Pollack A, Komaki R, Cox JD. Thymoma: treatment and prognosis. Int J Radiat Oncol Biol Phys. 1992;23(5):1037-43. [Medline].

  40. Wright CD, Wain JC, Wong DR. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. J Thorac Cardiovasc Surg. Nov 2005;130(5):1413-21. [Medline].

  41. Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg. Jan 2005;79(1):219-24. [Medline].

  42. Park MS, Chung KY, Kim KD. Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. Ann Thorac Surg. Sep 2004;78(3):992-7; discussion 997-8. [Medline].

  43. Rena O, Papalia E, Maggi G. World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer. Oct 2005;50(1):59-66. [Medline].

  44. Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg. Dec 2007;134(6):1477-83; discussion 1483-4. [Medline].

  45. Curran WJ Jr, Kornstein MJ, Brooks JJ, Turrisi AT 3rd. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. Nov 1988;6(11):1722-7. [Medline].

  46. Goldman L, Cecil RL, Bennett JC, eds. Cecil Textbook of Internal Medicine. WB Saunders Co; 2000.

  47. Graeber GM, Tamim W. Current status of the diagnosis and treatment of thymoma. Semin Thorac Cardiovasc Surg. Oct 2000;12(4):268-77. [Medline].

  48. Inoue M, Okumura M, Miyoshi S, et al. Impaired expression of MHC class II molecules in response to interferon- gamma (IFN-gamma) on human thymoma neoplastic epithelial cells. Clin Exp Immunol. Jul 1999;117(1):1-7. [Medline].

  49. Monden Y, Nakahara K, Iioka S, et al. Recurrence of thymoma: clinicopathological features, therapy, and prognosis. Ann Thorac Surg. Feb 1985;39(2):165-9. [Medline].

  50. Spigland N, Di Lorenzo M, Youssef S, et al. Malignant thymoma in children: a 20-year review. J Pediatr Surg. Nov 1990;25(11):1143-6. [Medline].

  51. Stephan JL, Galambrun C, Boucheron S, et al. Epstein-Barr virus--positive undifferentiated thymic carcinoma in a 12- year-old white girl. J Pediatr Hematol Oncol. Mar-Apr 2000;22(2):162-6. [Medline].

Previous
Next
 
Table 1. Comparison of the Different Classifications of Thymic Epithelial Tumors[26]
Clinicopathologic ClassificationWHO TypeTerminology of the Histogenetic Classification for the Histologic Subtypes of Thymic Epithelial Tumors
Benign thymomaA



AB



Medullary thymoma



Mixed thymoma



Malignant thymomas,



Category I



B1



B2



B3



Predominantly cortical thymoma



Cortical thymoma



Well-differentiated thymic carcinoma



Malignant thymomas,



Category II



CEpidermoid keratinizing (squamous cell) carcinoma



Epidermoid nonkeratinizing carcinoma



Lymphoepithelioma-like carcinoma



Sarcomatoid carcinoma (carcinosarcoma)



Clear cell carcinoma



Mucoepidermoid carcinoma



Undifferentiated carcinoma



Table. Macchiarini et al (1991)[34]
Cisplatin75 mg/m2 on day 13 courses repeated q3wk
Epirubicin100 mg/m2 on day 1
Etoposide120 mg/m2 on days 1, 3, and 5
Surgery and radiation



in patients with



complete or partial



response to chemotherapy



4500 cGy if complete



resection



6000 cGy if incomplete



resection



Table. Loehrer et al (1997)[35]
Cisplatin50 mg/m22-4 cycles q3wk
Doxorubicin50 mg/m2
Cyclophosphamide500 mg/m2
Followed by radiation54 Gy to the primary tumor and lymph nodes
Table. Venuta et al (1997)[36]
Cisplatin75-100 mg/m2 on day 1Repeated q3wk 3 times before surgery and 2 or 3 times after surgery
Epirubicin hydrochloride100 mg/m2 on day 1
Etoposide120 mg/m2 on days 1, 3, and 5
Postoperative radiation in patients with radical resection30 GyDelivered in 3 wk with 5 fractions per wk
Postoperative radiation in



patients with incomplete resection



50 GyDelivered in 5 wk with 5 fractions per wk
Table. Palmieri et al (1999)[37]
Octreotide1.5 mg/d SCIn patients shown to have



somatostatin receptors



Lanreotide30 mg/d SC q14dSwitch to this longer-acting



somatostatin analogue or depot form of octreotide if short-acting octreotide



is well tolerated



Prednisone0.6 mg/kg/d PO



for 3 mo, then



decreasing to 0.2 mg/kg



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.